Search News Archives
Follow us on
Conferences | Events

Media Partners

 

Lonza Expands Cell-Culture Portfolio with Quasi Vivo System

publication date: Mar 2, 2018
 | 
author/source: Lonza

Lonza-Expands-Cell-Culture-Portfolio-Quasi-Vivo-System 

Lonza-Expands-Cell-Culture-Portfolio-Quasi-Vivo-SystemLonza has announced the latest addition to its cell-culture product portfolio – the Quasi Vivo® System. The Quasi Vivo® Device consists of an advanced, interconnected fluidics system to create more physiologically relevant cell-culture conditions, helping researchers improve the predictive value of their studies.

This new product offering from Lonza is a result of a worldwide marketing and distribution agreement with Kirkstall – a biotechnology company based in Rotherham (UK).

A common issue faced by drug discovery scientists who use conventional in vitro culture systems is their poor translatability to humans. To address this problem, Kirkstall developed the Quasi Vivo® System, which consists of interconnected cell-culture chambers and a peristaltic pump to create a continuous flow of media over cells. As a result, cultures are exposed to more physiologically relevant conditions, increasing the predictive value of in vitro experiments.

The Quasi Vivo® System is available with three different culture chambers (QV500, QV600, and QV900) to support a wide range of applications, including submerged cell culture, co-culture and modeling of air-liquid and liquid-liquid interfaces. Not only is the Quasi Vivo® System easy to set up, it also enables close monitoring of variables during an experiment. Furthermore, the large scale and user configurability of the Quasi Vivo® System allows assays to be performed that are not possible using microfluidic systems.

"Building on Lonza’s industry-respected cell-culture portfolio, the addition of the Quasi Vivo® System is an important step forward in advancing the use of primary cells in biomedical research," said Dr Maureen Bunger, Product Manager for ADME/Tox Solutions at Lonza. "Some of the limitations of primary cells, such as short life-spans and unstable phenotypes, are reduced when cells are cultured in a dynamic fluid system."

She added: "The Quasi Vivo® System, which has been developed by Kirkstall’s scientists over the last 10 years, is an important addition to our portfolio of more than 100 different primary cell types and specialized media solutions."

Kirkstall’s CEO, Dr Malcolm Wilkinson, commented: "The Quasi Vivo® System complements so many of Lonza’s existing products. It is already used in more than 70 labs worldwide across a wide variety of applications, and we look forward to working closely with Lonza to ensure the number of researchers benefiting from the system increases rapidly."




 


Popular this Month

 

Win a PIPETBOY from the new Integra summer collection!

 

Great Savings off Selected GC Columns

 

CytoSMART raises 5.2 million Euros for further product innovation and growth

 

High Volume Sample Storage in Space Efficient 96-Well Format

 

Cherwell Publishes Guide on Sterility Testing

 

Effective Removal of DMSO from Stored Samples

 

ATL Webcast: A Practical Guide to Selecting the Right LIMS

 

Genetic study reveals how gut bacteria work to keep us healthy

 

Lonza Establishes Custom Cell Biology Services to Offer Unique Manufacturing and Testing Capabilities

 

Thermo Fisher Scientific Opens Food Safety Customer Solution Center in India

 

 


 

 


 

Can't find what you are looking for?

Search by company or by product


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd